nanodiag BW

The nanodiag BW future cluster uses nanopore technologies to detect epigenetic factors influencing diseases and to apply the resulting diagnostic and therapeutic solutions.


Dr. Peter D. Jones and Prof. Dr. Jannik Meyer support the nanodioag BW Cluster in the field of biomedical micro- and nanotechnology in the projects solid-state anopore analyzer and in innovation support measures.

The BMBF's high-tech strategy names health as one of the major global societal challenges. Groundbreaking findings from cutting-edge research show that epigenetic factors are causally involved in common and often fatal diseases, including cancers, diabetes, cardiovascular, mental, neurodegenerative and infectious diseases. These include the so-called post-translational modifications (PTM) of proteins. So far, these can only be detected with very complex mass spectrometry or with error-prone immunoassays. Recent research results show that miniaturized analysis systems based on nanopore technology will make it much easier, faster and more reliable to determine these modifications in the future - with the unique selling point that even isomers of the same mass can be differentiated.

The nanodiag BW future cluster pursues the vision of realizing such miniaturized analytical devices and processes and transforming them into disruptive diagnostic products, innovative services and spin-offs with high growth potential. In this way, epigenetic markers can be made accessible to routine diagnostics and the prevention, therapy and aftercare of common and severe diseases can be significantly improved.

Due to its high sensitivity, nanopore analysis in combination with new enrichment methods is particularly compatible with non- or minimally invasive sampling (liquid biopsy), so that no tissue sample needs to be taken for this purpose.

More information:

01.04.2023 - 31.03.2026
03ZU1208BG; 03ZU1208DD